Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States

Por Yousef Zakharia, Despina Thomaidou, Benjamin Li, Gordon Siu, Rebecca Levin, Anna Vlahiotis, Dharanija Rao, Giovanni Zanotti
Publicado em 2022-05-01